Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab add-on to brief intervention for migraine with medication overuse headache
NL-OMON58865Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of eptinezumab in chronic migraine, migraine and medication overuse headache (MOH), sponsored by Lundbeck. Primary endpoint: Change from baseline in the number of monthly headache days. Started Sep 2022; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migrainemigrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on NL-OMON58865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58865.